Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG(2) Monoclonal Antibody, in Healthy Volunteers

INTRODUCTION: VIS649 (sibeprenlimab), a humanized IgG(2) monoclonal antibody that inhibits APRIL, is being developed as a potential treatment for IgA nephropathy (IgAN). This phase 1, first-in-human, randomized, double-blind, single ascending dose study aimed to evaluate the safety, pharmacokinetics...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathur, Mohit, Barratt, Jonathan, Suzuki, Yusuke, Engler, Frank, Pasetti, Marcela F., Yarbrough, Jill, Sloan, Susan, Oldach, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091613/
https://www.ncbi.nlm.nih.gov/pubmed/35570983
http://dx.doi.org/10.1016/j.ekir.2022.01.1073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091613/
https://www.ncbi.nlm.nih.gov/pubmed/35570983
http://dx.doi.org/10.1016/j.ekir.2022.01.1073

Ejemplares similares